Targovax awarded NOK 9.8m research grant by the Research Council of Norway towards the TG mutant RAS program
Oslo, Norway, 15 December 2021 - Targovax ASA (OSE: TRVX) a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that the Research Council of Norway has awarded Targovax a NOK 9.8m research grant towards product and clinical development for the TG mutant KRAS cancer vaccine program.The Research Council of Norway has awarded the grant within the category “Innovation Project for the Industrial Sector”. Project title: “Development of targeted therapies for mutant RAS cancers”Awarded by: The Research Council of Norway